Smith & Nephew (SNN) Earning Somewhat Favorable Media Coverage, Analysis Shows

Media stories about Smith & Nephew (NYSE:SNN) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Smith & Nephew earned a news impact score of 0.15 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.3109873660653 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

SNN has been the subject of several analyst reports. Morgan Stanley downgraded shares of Smith & Nephew from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Zacks Investment Research downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Finally, Canaccord Genuity initiated coverage on shares of Smith & Nephew in a report on Wednesday, October 11th. They set a “buy” rating and a $42.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $44.00.

Shares of Smith & Nephew (NYSE:SNN) traded up $0.19 during trading hours on Thursday, hitting $34.78. 645,625 shares of the stock traded hands, compared to its average volume of 524,391. Smith & Nephew has a 12 month low of $29.76 and a 12 month high of $40.43. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 2.18. The firm has a market cap of $14,900.00, a PE ratio of 17.74, a price-to-earnings-growth ratio of 2.70 and a beta of 0.72.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.

Leave a Reply